

Datasheet: HCA403 BATCH NUMBER 167082

Description:	HUMAN ANTI OBINUTUZUMAB
Specificity:	OBINUTUZUMAB
Other names:	Afutuzumab
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD50319ia
Isotype:	lgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	•			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

Human IgG1 antibody (lambda light chain) selected from Bio-Rad's human antibody phage display libraries and expressed in a human cell line. This antibody is supplied as a liquid.

Preparation	Purified IgG prepared by affinity chromatography on Protein A
Source	HKB-11
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃)
Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml

Immunogen	Obinutuzumab
Specificity	Human Anti-Obinutuzumab Antibody, clone AbD50319ia is a paratope specific, inhibitory, anti-idiotypic antibody (Type 1) that specifically recognizes the free human monoclonal antibody drug obinutuzumab, and its biosimilar products. Consequently, this antibody can be used to measure free obinutuzumab levels in serum from patients.
	Clone AbD50319ia (HCA403) is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a positive control or calibrator in an anti-drug antibody (ADA) assay.
	Obinutuzumab (trade name Afutuzumab) is a Fc-glyco-engineered monoclonal IgG1/kappa antibody. It specifically targets the extracellular loop of the CD20 transmembrane antigen on the surface of non-malignant and malignant pre-B and mature B-lymphocytes, but not on hematopoietic stem cells, pro-B-cells, normal plasma cells or other normal tissue. In nonclinical studies, Obinutuzumab induces direct cell death and mediates antibody dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) through recruitment of FcvRIII positive immune effector cells. In addition, in vivo, Obinutuzumab mediates a low degree of complement dependent cytotoxicity (CDC). Hence, it is an immunosuppressive drug. Obinutuzumab is indicated for the combination treatment of patients with chronic lymphocytic leukemia and follicular lymphoma.
	View a summary of all anti-obinutuzumab antibodies.
Affinity	The monovalent intrinsic affinity of Human anti-Obinutuzumab Antibody, clone AbD50319ia was measured as $K_D = 0.562$ nM by real time, label-free molecular interaction analysis on immobilized obinutuzumab.
ELISA	Clone AbD50319ia may be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera together with clone AbD50514ia (<u>HCA404</u>) and clone AbD50104ia (<u>HCA405</u>). Protocol: <u>ADA bridging ELISA</u>
Storage	This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
	Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Guarantee	12 months from date of despatch
Acknowledgements	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and

Afutuzumab is a registered trademark of Genentech/ Roche and Biogen.

bio-rad.com/en-us/trademarks for details.

non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See

Health And Safety Information	Material Safety Datasheet documentation #10040 available at: https://www.bio-rad-antibodies.com/SDS/HCA403 10040	
Licensed Use	For <i>in vitro</i> . research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.	
Regulatory	For research purposes only	
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <u>HuCAL Antibodies Technical Manual</u> .	

Related Products

Recommended Useful Reagents

HISPEC ASSAY DILUENT (BUF049A)

HUMAN ANTI OBINUTUZUMAB (HCA404)

HUMAN ANTI OBINUTUZUMAB (HCA405)

HUMAN ANTI OBINUTUZUMAB (TZA048)

HUMAN ANTI OBINUTUZUMAB (TZA049)

HUMAN ANTI OBINUTUZUMAB:HRP (TZA049P)

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK002P)

 North & South
 Tel: +1 800 265 7376
 Worldwide
 Tel: +44 (0)1865 852 700
 Europe
 Tel: +49 (0) 89 8090 95 21

 America
 Fax: +1 919 878 3751
 Fax: +44 (0)1865 852 739
 Fax: +49 (0) 89 8090 95 50

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M426694:240220'

Printed on 03 May 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint